Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Multi-center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of BA3071 Alone and in Combination with Tislelizumab (an Investigational Anti-PD-1 Inhibitor)

Next Previous
Search
Trial Profile

A Phase 1/2 Multi-center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of BA3071 Alone and in Combination with Tislelizumab (an Investigational Anti-PD-1 Inhibitor)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BA 3071 (Primary) ; Tislelizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors BioAtla

    • Most Recent Events

    • 15 Nov 2021 According to a BioAtla media release, the company expects to initiate this trial by year end.
    • 12 May 2021 According to BioAtla media release, the Phase 1 dose-escalation trial is expected to commence in 2021.
    • 06 Oct 2020 According to a BioAtla media release, under the amended terms of the agreement, BeiGene will hold an exclusive global license to BA3071 and will be solely responsible for its global clinical development and commercialization and have the right to receive all profits on any future sales net of royalty payments to BioAtla.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top